10531-44-9

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-1-(5-BROMOTHIOPHEN-2-YL)ETHANONE is used as an intermediate in the synthesis of active pharmaceutical ingredients. Its unique structure and reactivity make it a valuable building block for creating new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 2-BROMO-1-(5-BROMOTHIOPHEN-2-YL)ETHANONE serves as an intermediate for the production of active ingredients in pesticides. Its properties and reactivity contribute to the development of effective and targeted pest control solutions.
Used in Organic Synthesis:
2-BROMO-1-(5-BROMOTHIOPHEN-2-YL)ETHANONE is used as a building block in organic synthesis for creating a wide range of organic molecules. Its bromine atoms and thiophene ring provide unique reactivity and structural features that can be exploited in the synthesis of various organic compounds.
Used as a Reagent in Organic Chemistry:
The presence of bromine in 2-BROMO-1-(5-BROMOTHIOPHEN-2-YL)ETHANONE makes it a useful reagent in certain chemical reactions. Its reactivity can be harnessed to facilitate specific transformations and reactions in organic chemistry.
Used in the Development of New Products and Materials:
The unique structure and properties of 2-BROMO-1-(5-BROMOTHIOPHEN-2-YL)ETHANONE make it a valuable tool in the development of new products and materials. Its versatility and reactivity can be utilized to create innovative solutions in various industries, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C6H4Br2OS/c7-3-4(9)5-1-2-6(8)10-5/h1-2H,3H2

Upstream product

• 88-15-3 2-Acetylthiophene 
• 5370-25-2 2-Acetyl-5-bromothiophene 
• 60-29-7 diethyl ether 
• 1003-09-4 2-bromothiophene 
• 598-21-0 2-Bromoacetyl bromide 
• 872-55-9 2-ethylthiophene 

Downstream Products

• 71683-02-8 3-(5-bromo-thiophen-2-yl)-3-oxo-propionitrile 
• 1254171-26-0 4-(5-bromothiophen-2-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole 
• 1245794-47-1 C₁₄H₁₁BrN₂S 
• 34801-14-4 4-(5-bromo-2-thienyl)-1,3-thiazol-2-amine 
• 340809-13-4 4-amino-5-(5-bromothiophene-2-carbonyl)-2-(phenylamino)thiophene-3-carbonitrile 

Relevant academic research and scientific papers

Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools

Thienylhalomethylketones, whose chemical, biological, and pharmaceutical data are here reported, are the first irreversible inhibitors of GSK-3β described to date. Their inhibitory activity is likely related to the cysteine residue present in the ATP-binding site, which is proposed as a relevant residue for modulation of GSK-3 activity. The good cell permeability of the compounds allows them to be used in different cell models. Overall, the results presented here support the potential use of halomethylketones as pharmacological tools for the study of GSK-3β functions and suggest a new mechanism for GSK-3β inhibition that may be considered for further drug design.

Based on isoxazole substitution of benzamide derivatives and anti-prostate cancer drug applications

The present invention discloses a class (I), formula (II) structure based on isoxazole substituted benzamide derivatives and antiprostate cancer drug applications, such isoxazole substituted benzamide derivatives, can effectively inhibit the activity of a

Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents

(+)-Usnic acid, a product of secondary metabolism in lichens, has displayed a broad range of biological properties such as antitumor, antimicrobial, antiviral, anti-inflammatory, and insecticidal activities. Interested by these pharmacological activities and to tap into its potential, we herein present the synthesis and biological evaluation of new usnic acid enaminone-conjugated 1,2,3-triazoles 10-44 as antimycobacterial agents. (+)-Usnic acid was condensed with propargyl amine to give usnic acid enaminone 8 with a terminal ethynyl moiety. It was further reacted with various azides A1-A35 under copper catalysis to give triazoles 10-44 in good yields. Among the synthesized compounds, saccharin derivative 36 proved to be the most active analogue, inhibiting Mycobacterium tuberculosis (Mtb) at an MIC value of 2.5 μM. Analogues 16 and 27, with 3,4-difluorophenacyl and 2-acylnaphthalene units, respectively, inhibited Mtb at MIC values of 5.4 and 5.3 μM, respectively. Among the tested Gram-positive and Gram-negative bacteria, the new derivatives were active on Bacillus subtilis, with compounds 18 [3-(trifluoromethyl)phenacyl] and 29 (N-acylmorpholinyl) showing inhibitory concentrations of 41 and 90.7 μM, respectively, while they were inactive on the other tested bacterial strains. Overall, the study presented here is useful for converting natural (+)-usnic acid into antitubercular and antibacterial agents via incorporation of enaminone and 1,2,3-triazole functionalities.

SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES

The invention provides compounds represented by the structural formula (1): wherein R1, R2, R3, R4, R5, R6 are as defined in the claims. The compounds are inhibitors of nucleases, and are useful in particular in a method of treatment and/or prevention of proliferative diseases, neurodegenerative diseases, and other genomic instability associated diseases.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER

The present invention relates to inhibitors of the oncogenic protein kinase ALK of formula (I) as herein described and pharmaceutical compositions thereof. The compounds of formula (I) are useful in the preparation of a medicament, in particular for the treatment of cancer.

SPIRO COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS

Disclosed are spiro compounds of formula (I), or stereomers, geometric isomers, tautomers, nitrogen oxides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof. The compounds can be used to treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore disclosed are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions in the treatment of HCV infection or hepatitis C disease.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

no abstract published

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.